As of 2025-06-30, the Intrinsic Value of Protagonist Therapeutics Inc (PTGX) is 44.85 USD. This PTGX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 55.69 USD, the upside of Protagonist Therapeutics Inc is -19.50%.
The range of the Intrinsic Value is 27.45 - 152.83 USD
Based on its market price of 55.69 USD and our intrinsic valuation, Protagonist Therapeutics Inc (PTGX) is overvalued by 19.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 27.45 - 152.83 | 44.85 | -19.5% |
| DCF (Growth 10y) | 74.39 - 438.45 | 125.01 | 124.5% |
| DCF (EBITDA 5y) | 22.73 - 24.54 | 23.61 | -57.6% |
| DCF (EBITDA 10y) | 61.77 - 71.76 | 66.54 | 19.5% |
| Fair Value | 22.67 - 22.67 | 22.67 | -59.30% |
| P/E | 8.57 - 35.16 | 16.93 | -69.6% |
| EV/EBITDA | 8.36 - 22.62 | 12.71 | -77.2% |
| EPV | 3.92 - 4.42 | 4.17 | -92.5% |
| DDM - Stable | 7.75 - 29.85 | 18.80 | -66.2% |
| DDM - Multi | 12.04 - 37.41 | 18.38 | -67.0% |
| Market Cap (mil) | 3,451.67 |
| Beta | 0.37 |
| Outstanding shares (mil) | 61.98 |
| Enterprise Value (mil) | 3,312.01 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.46% |
| Cost of Debt | 5.00% |
| WACC | 6.57% |